Linagliptin

Drug Profile

Linagliptin

Alternative Names: BI 1356; BI 1356 BS; Dipeptidyl peptidase IV inhibitor - Boehringer Ingelheim; Ondero; Tradjenta; Trajenta; Trayenta; Trazenta

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly
  • Class Alkynes; Antihyperglycaemics; Piperidines; Purines; Quinazolines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Diabetic nephropathies

Most Recent Events

  • 15 Dec 2016 Committee for Medicinal Products for Human Use (CHMP) of EMA adopts a positive opinion recommending approval of linagliptin for extension to an existing indication of Type-2 diabetes mellitus
  • 19 Sep 2016 Eli Lilly and Boehringer Ingelheim plan a phase III trial for Type-2 diabetes mellitus (Adjunctive treatment) in China (PO) (NCT02897349)
  • 01 Sep 2016 Phase-III clinical trials in Type-2 diabetes mellitus (Adjunctive treatment) in China (PO) (NCT02897349)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top